Jeng Her
Chief Executive Officer AP Biosciences
Dr. Jeng Her is the founder and CEO of AP Biosciences. He had received a bachelor’s degree in Physics from the National Taiwan University, then turned into biology and earned a Ph.D. degree in Microbiology and Immunology from the University of Virginia in 1993. Before setting up AP Biosciences in Taiwan, he had co-founded KaloBios Pharmaceuticals in the Silicon Valley soon after his post-doctoral training at Bristol-Myers Squibb and DNAX Research Institute (now part of Merck). At KaloBios, he co-invented the antibody Humaneering™, a technology which converts non-human antibodies into engineered human-like antibodies with sequences close to the germline to minimize immunogenicity. The technology was then licensed to Novartis non-exclusively for $32M. In 2013, KaloBios went public on NASDAQ with three antibodies in clinical trials, including KB001 for ventilator-associated pneumonia, which was licensed to Sanofi-Pasteur for $270 million.
Seminars
- Reviewing differences in bispecific modalities including dual inhibitors, agonists, T-cell and other immune-cell engagers
- How are novel targets and formats expanding engager pipelines across both blood and solid tumors?
- What does this mean for the potential first-in-class engager approvals?
- How can engagers and bispecifics be complementary to other drug modalities to improve patient outcomes?
